PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage

PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD franchise declines, with Q1 2026 product revenue up 47% year-over-year and strong patient onboarding momentum. PTCT's partnership with Novartis on votoplam for Huntington's disease offers de-risked late-stage upside, while a $1.9B cash position provides strategic flexibility and reduces near-term dilution risk.

Seeking Alpha • May 10, 2026

PTC Therapeutics Q1 Earnings Call Highlights

PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.

MarketBeat • May 8, 2026

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –    – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback – WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026.

PRNewsWire • May 7, 2026

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $10.04 per share a year ago.

Zacks Investment Research • May 7, 2026

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • May 7, 2026

Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.

Zacks Investment Research • May 6, 2026

PTC Therapeutics to Participate in Upcoming Investor Conferences

WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conference 2026 Tuesday, May 12 at 8:40 a.m.

PRNewsWire • May 4, 2026

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 30, 2026